SHELTON, Conn., June 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
